Research Topics
Species | Claudine IsaacsSummaryAffiliation: Georgetown University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2Anna Marie Mulligan
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
Breast Cancer Res 13:R110. 2011..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...- Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriersEitan Friedman
The Suzanne Levy Gertner Oncogenetics Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Breast Cancer Res 8:R15. 2006.... - Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriersSusan L Neuhausen
Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
Breast Cancer Res 11:R76. 2009..In this study, we investigate the association of variants in genes involved in IGF signaling and risk of breast cancer in women who carry deleterious BRCA1 and BRCA2 mutations... - Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer riskLuisel J Ricks-Santi
Howard University Cancer Center, 2041 Georgia Ave, NW Washington, DC 20060, USA
BMC Cancer 11:278. 2011..Here, we explore the relationships between the MSA and the Rad51 gene, which encodes a DNA repair enzyme that interacts with BRCA1 and BRCA2, in BRCA1 mutation carriers and women with sporadic breast cancer... - Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)Federico Canzian
German Cancer Research Center DKFZ, Heidelberg, Germany
BMC Cancer 9:257. 2009..We studied the association between breast cancer risk and polymorphisms in genes that code for GNRH1 and its receptor (GNRHR) in the large National Cancer Institute Breast and Prostate Cancer Cohort Consortium (NCI-BPC3)... 
A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patientsClaudine Isaacs
Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Washington, DC, 20057, USA
Breast Cancer Res Treat 93:125-34. 2005..This Phase III randomized multicenter trial compared progression-free (PFS) and overall survival (OS) for autologous peripheral blood stem cell (aPBSC) transplantation with or without immunotherapy in high-risk breast cancer patients...- Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancerClaudine Isaacs
Department of Medical Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20007 2197, USA
Breast Cancer Res Treat 71:103-12. 2002..These findings indicate a need for better education about screening guidelines for high-risk women... 
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancerClaudine Isaacs
Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road, Washington, DC 20057, USA
Breast Cancer Res Treat 125:137-43. 2011..Toxicities occurred frequently resulting in a high rate of discontinuation...- BRCA1/2 test results impact risk management attitudes, intentions, and uptakeSuzanne C O'Neill
Cancer Control Program and Fisher Center for Familial Cancer Research, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
Breast Cancer Res Treat 124:755-64. 2010..001). Receipt of BRCA1/2 mutation test results impacts how carriers see the positive aspects of RRO and RRM and their surgical intentions. Both the positive and negative aspects predict uptake of surgery... - Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patientsMarc D Schwartz
Department of Oncology, Lombardi Comprehensive Cancer Center, Cancer Control Program, Georgetown University School of Medicine, Suite 317, 2233 Wisconsin Avenue, Northwest, Washington, DC 20007, USA
Cancer Epidemiol Biomarkers Prev 14:1003-7. 2005..In this study, we evaluated factors associated with the decision to undergo BRCA1/BRCA2 gene testing at the time of initial breast cancer diagnosis... - Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillanceMarc D Schwartz
Department of Oncology, Cancer Control Program, Jess and Mildred Fisher Center for Familial Cancer Research, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
Cancer 118:510-7. 2012..We evaluated long-term uptake and predictors of risk-reducing mastectomy (RRM), risk-reducing bilateral salpingo-oophorectomy (RRBSO), chemoprevention, and cancer screening among women at a mean of 5.3 years after testing... - Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patientsMarc D Schwartz
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
J Clin Oncol 22:1823-9. 2004..In the present study, we prospectively evaluated the impact on surgical decision-making of pretreatment genetic counseling and BRCA1/BRCA2 testing among breast cancer patients at high-risk for carrying a mutation... - Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testingBeth N Peshkin
Lombardi Cancer Center, Georgetown University, Washington, DC 20007, USA
Cancer Epidemiol Biomarkers Prev 11:1115-8. 2002..Noncarriers had very good adherence to general population screening guidelines... - Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancerLuciane R Cavalli
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
Cancer Genet Cytogenet 149:38-43. 2004..Our results suggest that there is a field effect of early genetic events preceding morphologic changes in the mammary glands of BRCA mutation carriers... - Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testingMarc D Schwartz
Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20007, USA
J Clin Oncol 21:4034-41. 2003..In this study, we prospectively examined the impact of BRCA1/2 testing on the utilization of prophylactic oophorectomy and ovarian cancer screening. Participants and.. - Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfactionMarc D Schwartz
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
Health Psychol 28:11-9. 2009..To help BRCA1/2 carriers make this decision, the authors developed a computer-based interactive decision aid that was tested against usual care in a randomized controlled trial... - Management updates for women with a BRCA1 or BRCA2 mutationRachel Nusbaum
Lombardi Comprehensive Cancer Center, Jess and Mildred Fisher Center for Familial Cancer Research, Washington, DC, USA
Mol Diagn Ther 11:133-44. 2007..Currently, BRCA carrier status is not used as an independent prognostic factor regarding systemic treatment options... - A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activityVered Stearns
Breast Cancer Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
Clin Cancer Res 10:8332-40. 2004..We chose tamoxifen to establish proof of principal with a known effective agent... - Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testingKenneth P Tercyak
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007 2401, USA
J Clin Oncol 25:285-91. 2007..In this study, we compared the impact of BRCA1/2 genetic test result and CPM on these outcomes among newly diagnosed breast cancer patients who opted for CPM at the time of their definitive surgical treatment versus patients who did not... - Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivorsKristi D Graves
Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
Breast Cancer Res Treat 104:321-9. 2007..To reduce the risk of contralateral breast cancer, some patients opt for prophylactic surgery of the unaffected breast (contralateral prophylactic mastectomy, CPM) in addition to mastectomy of the affected breast... - Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901Jeanne S Mandelblatt
Lombardi Comprehensive Cancer Center, 3300 Whitehaven Blvd, Washington, DC 20007, USA
J Clin Oncol 30:2609-14. 2012..It will be important to re-evaluate the impact of decision styles when there is greater empirical evidence about the benefits and risks of chemotherapy in older patients... - Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choiceKristi D Graves
Department of Oncology, Cancer Control Program, Breast Cancer Program, Jess and Mildred Fisher Center for Familial Cancer Research, Lombardi Comprehensive Cancer Center, Washington, District of Columbia 20007, USA
Cancer Epidemiol Biomarkers Prev 21:445-55. 2012..We conducted the first long-term prospective study of psychosocial outcomes in a U.S. sample of women who had BRCA1/2 testing... - Perceived risk of breast cancer among Latinas attending community clinics: risk comprehension and relationship with mammography adherenceKristi D Graves
Department of Oncology, Cancer Control Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 20007, USA
Cancer Causes Control 19:1373-82. 2008..To describe breast cancer risk perceptions, determine risk comprehension, and evaluate mammography adherence among Latinas... - Predictors of enrollment into a familial cancer registry by individuals at high risk for BRCA1/2Kristi D Graves
Cancer Control Program, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street, Northwest, Suite 4100, Washington, DC 20007, USA
Cancer Epidemiol Biomarkers Prev 16:2763-7. 2007..We also sought to identify the factors associated with provision of a blood sample to the FCR... - Evaluation and management of women with BRCA1/2 mutationsBeth N Peshkin
Oncology and Medicine Department of Cancer Control, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC, USA
Oncology (Williston Park) 19:1451-9; discussion 1459-68 1474. 2005..We conclude with a review and appraisal of the various options for breast and ovarian cancer risk reduction and screening options for women with a BRCA1 or BRCA2 mutation... - Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physiciansBeth N Peshkin
CGC, 2233 Wisconsin Ave, NW, Suite 317, Washington, DC 20007, USA
J Clin Oncol 21:4322-8. 2003..To assess physician recommendations about the use of tamoxifen in premenopausal BRCA1 and BRCA2 mutation carriers... - Practical aspects of delivering hereditary cancer risk counselingTiffani A Demarco
Jess and Mildred Fisher Center for Familial Cancer Research, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
Semin Oncol 34:369-78. 2007.... - Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trialVered Stearns
Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC, USA
J Clin Oncol 23:6919-30. 2005..A secondary objective was to evaluate quality of life (QOL) parameters... - Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sampleMarc D Schwartz
Department of Oncology, Georgetown University, and Lombardi Cancer Center, Washington, DC 20007, USA
J Clin Oncol 20:514-20. 2002..The objective of this study was to examine the long-term psychologic impact of receiving BRCA1/2 test results within a clinic-based testing program... - Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancerMinetta C Liu
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007 2198, USA
J Clin Oncol 27:5153-9. 2009..We conducted a prospective study to demonstrate that CTC results correlate strongly with radiographic disease progression at the time of and in advance of imaging... - Utilizing prognostic and predictive factors in breast cancerDeepa S Subramaniam
Georgetown University Medical Center, Lombardi Cancer Center, 3800 Reservoir Road, Washington, DC 20007, USA
Curr Treat Options Oncol 6:147-59. 2005..Therefore, new data must be interpreted with caution... - Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RSNadiyah Sulayman
Department of Oncology, The Fisher Center for Familial Cancer Research, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC 20007, USA
J Cancer Epidemiol 2012:728290. 2012..These data should be confirmed in prospective samples, as these poorer outcomes could be amenable to intervention... - Providers' perceptions and practices regarding BRCA1/2 genetic counseling and testing in African American womenKristi D Graves
Lombardi Comprehensive Cancer Center, Cancer Control Program, Fisher Center for Familial Cancer Research, Georgetown University, Washington, DC 20007, USA
J Genet Couns 20:674-89. 2011..Results have implications for physician and patient education regarding appropriate referrals to and uptake of genetic services in at-risk African American women... - BRCA1/2 mutations and triple negative breast cancersBeth N Peshkin
Fisher Center for Familial Cancer Research, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC 20007 2401, USA
Breast Dis 32:25-33. 2010..Identifying women at increased risk is critical as knowledge of mutation status may impact surgical and systemic treatment in newly diagnosed patients, as well as recommendations for ovarian cancer risk management... - Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physiciansJeanne S Mandelblatt
Georgetown University School of Medicine and Lombardi Comprehensive Cancer Center, Washington, DC, USA
J Clin Oncol 28:3146-53. 2010..Breast cancer chemotherapy decisions in patients > or = 65 years old (older) are complex because of comorbidity, toxicity, and limited data on patient preference. We examined relationships between preferences and chemotherapy use... - Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patientsClaudine Isaacs
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
Breast Cancer Res Treat 84:99-105. 2004..One NAF sample from a BRCA1 patient showed a mtDNA mutation. Our data demonstrates the feasibility of performing molecular studies using the free DNA present in the ductal fluid, while the intact cells can be used for cytologic studies... - Prediction of benefit from adjuvant treatment in patients with breast cancerJennifer Eng-Wong
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007 2113, USA
Clin Breast Cancer 10:E32-7. 2010..This concept is currently being evaluated in multiple well-designed clinical trials... - BRCA mutation testing in determining breast cancer therapyKaren Lisa Smith
Department of Medicine, Division of Hematology and Oncology, Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
Cancer J 17:492-9. 2011..In addition, the sensitivity of BRCA mutation-associated breast cancer to endocrine therapy, platinum chemotherapy, and poly (ADP-ribose) polymerase inhibitors is reviewed... - Venous thromboembolic disease and stroke in women taking tamoxifen for breast cancer chemopreventionClaudine Isaacs
Clinical Breast Cancer Program, Lombardi Comprehensive Cancer Center, Georgetown University, USA
Clin Adv Hematol Oncol 3:913-4. 2005 - A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancerVered Stearns
Department of Medicine, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, USA
Clin Cancer Res 9:124-33. 2003.... - Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study GroupTimothy R Rebbeck
Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania, Philadelphia, PA 19104-6021, USA
J Clin Oncol 22:1055-62. 2004..CONCLUSION: Bilateral prophylactic mastectomy reduces the risk of breast cancer in women with BRCA1/2 mutations by approximately 90%... - Hormone therapy and the risk of breast cancer in BRCA1 mutation carriersAndrea Eisen
Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
J Natl Cancer Inst 100:1361-7. 2008.... - A comparison of bilateral breast cancers in BRCA carriersJeffrey N Weitzel
The Centre for Research in Women s Health, 790 Bay Street, Toronto, Ontario, Canada M5G 1N8
Cancer Epidemiol Biomarkers Prev 14:1534-8. 2005..It is generally believed that the two cancers represent independent events. However, the extent of concordance between the first and second tumors with respect to hormone receptor expression and other pathologic features is unknown... - Rapid progression of prostate cancer in men with a BRCA2 mutationS A Narod
Women s College Research Institute, 790 Bay Street, 7th Floor, Women s College Hospital, University of Toronto, Toronto, Ontario, Canada
Br J Cancer 99:371-4. 2008..0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation... - The Cancer Genetics Network: recruitment results and pilot studiesHoda Anton-Culver
Epidemiology Division, College of Medicine, University of California, Irvine, 92697 7550, USA
Community Genet 6:171-7. 2003.... - Cancer variation associated with the position of the mutation in the BRCA2 geneJan Lubinski
Hereditary Cancer Center Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin, Poland
Fam Cancer 3:1-10. 2004..0; P = 0.03) compared to families of other ethnic origins. In conclusion, both the position of mutation and the ethnic background of the family appear to contribute to the phenotypic variation observed in families with BRCA2 mutations... - Smoking and the risk of breast cancer among carriers of BRCA mutationsParviz Ghadirian
Epidemiology Research Unit, Centre Hospitalier del Universite de Montreal Hotel Dieu, Faculty of Medicine, Universite de Montreal, Montreal, Quebec, Canada
Int J Cancer 110:413-6. 2004..03; 95% CI 0.83 to l.28) or before the first pregnancy (OR = 1.09; 95% CI = 0.90 to 1.33). In conclusion, contrary to our previous report, smoking does not appear to be a risk factor for breast cancer among carriers of BRCA mutations... - Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control studySteven A Narod
Centre for Research on Women s Health, University of Toronto, Ontario, Canada
Lancet Oncol 7:402-6. 2006..We aimed to assess whether exposure to ionising radiation through mammography screening was associated with risk of breast cancer in BRCA1 or BRCA2 mutation carriers... - Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos
Centre for Research in Women s Health, University of Toronto, Women s College Hospital, 790 Bay Street, 7th Floor, Totonto, Ontario M5G 1N8, Canada
Cancer Causes Control 16:667-74. 2005..46; 95% CI 0.30-0.69). This study implicates early age at menarche as a determinant of breast cancer among women with a BRCA1 mutation... - Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersSteven A Narod
The Centre for Research on Women s Health, University of Toronto, 790 Bay Street, Toronto, Ontario M5G 1N8, Canada
J Natl Cancer Inst 94:1773-9. 2002..We examined whether this association is seen in women at high risk of breast cancer because they carry a mutation in one of two breast cancer susceptibility genes, BRCA1 and BRCA2... - Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutationsTimothy R Rebbeck
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104 6021, USA
N Engl J Med 346:1616-22. 2002..We investigated whether this procedure reduces the risk of cancers of the coelomic epithelium and breast in women who carry such mutations... - All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test resultsChanita Hughes
Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Am J Med Genet 107:143-50. 2002.... - Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriersAntonis C Antoniou
Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
Am J Hum Genet 82:937-48. 2008.... - Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriersTara M Friebel
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
Clin Breast Cancer 7:875-82. 2007..The availability of these risk-reduction strategies is an important consideration in the decision to undergo genetic testing... - Characterization of BRCA1 and BRCA2 mutations in a large United States sampleSining Chen
Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
J Clin Oncol 24:863-71. 2006..Existing studies have focused on Ashkenazi Jews (AJ) or on families from outside the United States. In this article, we consider the US population using the largest US-based cohort to date of both AJ and non-AJ families... - Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort studySusan M Domchek
Abramson Cancer Centre, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6021, USA
Lancet Oncol 7:223-9. 2006..Together, these data could give information to women who are considering genetic testing... - Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study GroupTimothy R Rebbeck
Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
J Clin Oncol 23:7804-10. 2005..Thus, we evaluated whether the breast cancer risk reduction conferred by BPO in BRCA1/2 mutation carriers is altered by use of post-BPO HRT... - Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancerLori J Pierce
Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI 48109 0010, USA
J Clin Oncol 24:2437-43. 2006..We compared the outcome of breast-conserving surgery and radiotherapy in BRCA1/2 mutation carriers with breast cancer versus that of matched sporadic controls... - Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos
Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Toronto, ON, Canada
Breast Cancer Res 7:R833-43. 2005..We asked whether there is an association between changes in body weight and the risk of breast cancer in women who carry a mutation in either breast cancer susceptibility gene, BRCA1 or BRCA2... - Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos
Centre for Research in Women s Health, 790 Bay Street, 7th Floor, Women s College Hospital, University of Toronto, Toronto, Ontario, Canada M5G 1N8
Gynecol Oncol 100:83-8. 2006..This association has not been evaluated in BRCA1 or BRCA2 mutation carriers who face very high lifetime risks of both breast and ovarian cancers... - Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos
Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Room 750, 790 Bay Street, 7th Floor, Toronto, ON M5G 1N8, Canada
Breast Cancer Res Treat 105:221-8. 2007..Nonetheless, BRCA mutation carriers opting for a prophylactic oophorectomy as a breast and/or ovarian cancer risk-reducing strategy should complete childbearing prior to age 40 when this prevention modality is most effective... - Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriersAndre Nkondjock
Epidemiology Research Unit, Research Centre, Centre Hospitalier de Universitaire de Montréal, CHUM Hotel Dieu, Montreal, Canada
Int J Cancer 118:103-7. 2006..These results suggest that among women with BRCA gene mutation, coffee consumption is unlikely to be harmful and that high levels of consumption may in fact be related to reduced breast cancer risk... - AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 studyFergus J Couch
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 16:1416-21. 2007..In summary, the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers... - Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening studyConstance D Lehman
Department of Radiology, University of Washington Medical Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, G3 200, Seattle, WA 98109 1023, USA
Radiology 244:381-8. 2007..To prospectively determine cancer yield, callback and biopsy rates, and positive predictive value (PPV) of mammography, magnetic resonance (MR) imaging, and ultrasonography (US) in women at high risk for breast cancer... - Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective studyNoah D Kauff
Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
J Clin Oncol 26:1331-7. 2008.... - Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study GroupKelly A Metcalfe
Lawrence Bloomberg Faculty of Nursing, University of Toronto, Canada
J Clin Oncol 26:1093-7. 2008..To evaluate the rate of prophylactic contralateral mastectomy in an international cohort of women with hereditary breast cancer and to evaluate the predictors of uptake of preventive surgery... - RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studiesAntonis C Antoniou
Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, CB1 8RN, UK
Am J Hum Genet 81:1186-200. 2007..Thus, 135G-->C may modify the risk of breast cancer in BRCA2 mutation carriers by altering the expression of RAD51. RAD51 is the first gene to be reliably identified as a modifier of risk among BRCA1/2 mutation carriers... - Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriersCarey A Cullinane
City of Hope National Medical Center, Duarte, CA, USA
Int J Cancer 117:988-91. 2005..Among BRCA2 carriers, increasing parity was associated with a significant increase in the risk of breast cancer before age 50 and this increase was greatest in the 2-year period following a pregnancy... - Management of women at increased risk for hereditary breast cancerKaren Lisa Smith
Washington Cancer Institute, Washington Hospital Center, Washington DC 20010, USA
Breast Dis 27:51-67. 2006..Finally, the management of women at risk for hereditary breast cancer in whom deleterious mutations are not identified is reviewed... - Validity of models for predicting BRCA1 and BRCA2 mutationsGiovanni Parmigiani
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21205 2011, USA
Ann Intern Med 147:441-50. 2007..At least 7 models for estimating the probabilities of having a mutation are used widely in clinical and scientific activities; however, the merits and limitations of these models are not fully understood... - Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control studyAndrea Eisen
Toronto Sunnybrook Regional Cancer Center, Toronto, ON, Canada
J Clin Oncol 23:7491-6. 2005.... - The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancersP Kelly Marcom
Siteman Comprehensive Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8056, St Louis, MO, USA
Breast Cancer Res Treat 102:43-9. 2007..The efficacy of the aromatase inhibitor letrozole in combination with trastuzumab was therefore tested in a Phase 2 study... - Breast cancer-related pseudocirrhosis and esophageal varicesVeena Chandrakar
Breast J 11:301-2. 2005 - Analysis of co-aggregation of cancer based on registry dataAbigail G Matthews
Massachusetts General Hospital Biostatistics Center, Boston, MA 02114, USA
Community Genet 9:87-92. 2006..018), and co-aggregation of hematopoietic and (non-ovarian) gynecologic cancers (adjusted p = 0.01). CONCLUSION: This analysis identified familial aggregation of cancers for which a genetic component has yet to be established...
Research Grants
- CANCER GENETICS NETWORKClaudine Isaacs; Fiscal Year: 2006....